Clinical and radiological characteristics of 206 cancer-associated SSPE cases
| Characteristic . | Categories . | N (%) . |
|---|---|---|
| Sex | Female | 87 (42.2) |
| ECOG performance status | 0 | 46 (22.7) |
| 1 | 94 (46.3) | |
| 2 | 33 (16.3) | |
| 3 | 25 (12.3) | |
| 4 | 5 (2.5) | |
| Cancer type* | ||
| Lung | 39 (18.9) | |
| Colorectal | 18 (8.7) | |
| Breast | 18 (8.7) | |
| Hematologic | 17 (8.3) | |
| Urologic | 17 (8.3) | |
| Gynecologic | 15 (7.3) | |
| Sarcoma | 15 (7.3) | |
| Esophageal | 11 (5.3) | |
| Pancreatic | 9 (4.4) | |
| Gastric | 6 (2.9) | |
| Other | 41 (19.9) | |
| AJCC stage† | 1 | 9 (4.7) |
| 2 | 14 (7.4) | |
| 3 | 28 (14.7) | |
| 4 | 139 (73.2) | |
| Cancer status | Active disease | 17 7(85.9) |
| Remission within 2 y | 17 (8.3) | |
| >2 y since remission | 12 (5.8) | |
| Central nervous tumor or metastasis | 21 (10.2) | |
| Lung or pleural metastasis | 101 (49) | |
| Liver metastasis | 43 (20.9) | |
| Active chemotherapy | 108 (53.2) | |
| Endocrine therapy | 11 (5.4) | |
| Antiangiogenic therapy | 21 (10.3) | |
| Major surgery within 30 d before SSPE | 25 (12.) | |
| History of venous thrombosis | 23 (11.2) | |
| Other indication for long-term anticoagulation | 30 (14.6) | |
| Concurrent antiplatelet therapy | 35 (17) | |
| Obesity | 68 (33) | |
| Concurrent use of erythropoietin agents | 1 (0.5) | |
| Type of CT study | CT chest PE protocol | 68 (33) |
| Contrast-enhanced CT | 138 (67) | |
| Single SSPE | 139 (70.9) | |
| Right pulmonary artery location | 132 (64.1) | |
| RV/LV ratio >1 | 11 (5.3) |
| Characteristic . | Categories . | N (%) . |
|---|---|---|
| Sex | Female | 87 (42.2) |
| ECOG performance status | 0 | 46 (22.7) |
| 1 | 94 (46.3) | |
| 2 | 33 (16.3) | |
| 3 | 25 (12.3) | |
| 4 | 5 (2.5) | |
| Cancer type* | ||
| Lung | 39 (18.9) | |
| Colorectal | 18 (8.7) | |
| Breast | 18 (8.7) | |
| Hematologic | 17 (8.3) | |
| Urologic | 17 (8.3) | |
| Gynecologic | 15 (7.3) | |
| Sarcoma | 15 (7.3) | |
| Esophageal | 11 (5.3) | |
| Pancreatic | 9 (4.4) | |
| Gastric | 6 (2.9) | |
| Other | 41 (19.9) | |
| AJCC stage† | 1 | 9 (4.7) |
| 2 | 14 (7.4) | |
| 3 | 28 (14.7) | |
| 4 | 139 (73.2) | |
| Cancer status | Active disease | 17 7(85.9) |
| Remission within 2 y | 17 (8.3) | |
| >2 y since remission | 12 (5.8) | |
| Central nervous tumor or metastasis | 21 (10.2) | |
| Lung or pleural metastasis | 101 (49) | |
| Liver metastasis | 43 (20.9) | |
| Active chemotherapy | 108 (53.2) | |
| Endocrine therapy | 11 (5.4) | |
| Antiangiogenic therapy | 21 (10.3) | |
| Major surgery within 30 d before SSPE | 25 (12.) | |
| History of venous thrombosis | 23 (11.2) | |
| Other indication for long-term anticoagulation | 30 (14.6) | |
| Concurrent antiplatelet therapy | 35 (17) | |
| Obesity | 68 (33) | |
| Concurrent use of erythropoietin agents | 1 (0.5) | |
| Type of CT study | CT chest PE protocol | 68 (33) |
| Contrast-enhanced CT | 138 (67) | |
| Single SSPE | 139 (70.9) | |
| Right pulmonary artery location | 132 (64.1) | |
| RV/LV ratio >1 | 11 (5.3) |
AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Oncology Group; RV/LV, right ventricular/left ventricular; SSPE, subsegmental pulmonary embolism.
Patients had multiple concurrent malignancies.
Calculated based on the number of patients (N = 190) classified using AJCC system, when available and applicable.